Immunoassay Systems | IDS 主营:Immunoassay Systems | IDS试剂盒授权代理商
服务电话: 4009687988
产品目录
联系我们
产品中心
所在位置:

Ostase® BAP EIA

  • 如果您对该产品感兴趣的话,可以
  • 产品名称:Ostase® BAP EIA
  • 产品型号:AC-20F1
  • 产品展商:其它品牌
  • 产品文档:无相关文档
简单介绍

品名:Ostase® BAP EIA 货号:AC-20F1

产品描述
Code: AC-20F1
Certification:

CE Marked
FDA Cleared

Clinical Area: Bone Metabolism
Type: Manual
Format: EIA
RUO/IVD: IVD
Number of Tests: 96 (40 samples in duplicate)
Sample Type: Serum
Sample Volume: 50 μL
Assay Range: 7-90 μg/L

Unique Features

  • Fast turnaround time – results in approximately half the time of other manual assays. (1h 15 mins. total incubation with <30 mins. hands-on time)
  • Measures bone specific alkaline phosphatase (BAP) with low interference from other alkaline phosphatase isoforms
  • Excellent limit of detection (<1.0 μg/L)
  • Clinically relevant assay range – accommodates samples in a wide dynamic range (7-90 μg/L)
  • Excellent correlation with automated methods
  • Complementary – ideal companion product to Immunodiagnostic Systems Limited continually growing bone marker range
  • A complete assay panel supporting bone disease management

The Ostase® BAP EIA Assay is an in-vitro device indicated for the quantitative measurement of bone-specific alkaline phosphatase (BAP), an indicator of osteoblastic activity in human serum1,2.

This device is intended to be used as an aid in the management of postmenopausal osteoporosis and Paget’s disease.

Ostase® is a registered trademark of Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc.

Serum levels of BAP are believed to reflect the metabolic status of osteoblasts. An accurate assessment of bone metabolism is critical for determining the severity of metabolic bone disease and responses to therapy.

Measurement of serum levels of BAP has been shown to be useful in evaluating patients with Paget’s disease, osteomalacia, primary hyperparathyroidism, renal osteodystrophy, osteoporosis and metastases to bone.

Cavalier E et al., Inter-method variability in bone alkaline phosphatase measurement: Clinical impact on the management of dialysis patients. Clin Biochem. 2014 Sep;47(13-14):1227-30.

Raisz L et al., Comparison of the effects of oestrogen alone and oestrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrin Metab. 1996; 81:37-43.


产品留言
标题
联系人
联系电话
内容
验证码
点击换一张
注:1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!